Skip to main content
SpringerLink
Log in

Relevant CYP450-mediated Drug Interactions in the ICU

  • Conference paper
Intensive Care Medicine

  • 1358 Accesses

Abstract

As multiple drug therapies are often used at the same time, the potential for clinically significant drug interactions in intensive care unit (ICU) patients is large [1]. Moreover, disease-related factors, such as altered drug distribution, renal insufficiency, and hepatic disease or altered protein binding, typically occurring in the critically ill will contribute to the wide interindividual variability in drug exposure and response and to the high risk of drug interactions [2]. The majority of drugs used in the ICU are metabolized by the iso-enzymes of the cytochrome P450 (CYP450) system [3]. This chapter provides a practical overview of CYP450-mediated drug interactions with high relevance to ICU patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kopp BJ, Erstad BL, Allen ME, Theodorou AA, Priestley G (2006) Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 34: 415–425

    Article  PubMed  Google Scholar 

  2. Krishnan V, Murray P (2003) Pharmacologic issues in the critically ill. Clin Chest Med 24: 671–688

    Article  PubMed  Google Scholar 

  3. Mann HJ(2006) Drug-associated disease: cytochrome P450 interactions. Crit Care Clin 22: 329–345

    Article  CAS  PubMed  Google Scholar 

  4. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352: 2211–2221

    Article  CAS  PubMed  Google Scholar 

  5. Lewis DF (2004) 57 varieties: the human cytochromes P450. Pharmacogenomics 5: 305–318

    Article  CAS  PubMed  Google Scholar 

  6. Lin JH, Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361–390

    Article  CAS  PubMed  Google Scholar 

  7. Pirmohamed M, Park BK (2003) Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicol 192: 23–32

    Article  CAS  Google Scholar 

  8. Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5: 235–243

    Article  CAS  PubMed  Google Scholar 

  9. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 38: 111–180

    Article  CAS  PubMed  Google Scholar 

  10. Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions. An update. Arch Intern Med 162: 985–992

    CAS  Google Scholar 

  11. Gerson LB, Triadafilopoulos G (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13: 611–616

    Article  CAS  PubMed  Google Scholar 

  12. Czock D, Keller F, Rasche FM, Häussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44: 61–98

    Article  CAS  PubMed  Google Scholar 

  13. Perucca E (2005) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61: 246–255

    Article  Google Scholar 

  14. Pai MP, Momary KM, Rodvold KA (2006) Antibiotic drug interactions. Med Clin N Am 90: 1223–1255

    Article  CAS  PubMed  Google Scholar 

  15. Saad AH, DePestel D, Carver P (2006) Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26: 1730–1744

    Article  CAS  PubMed  Google Scholar 

  16. Doherty MM, Charman WH (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism. Clin Pharmacokinet 41: 235–253

    Article  CAS  PubMed  Google Scholar 

  17. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O’Mara EM, Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64: 133–143

    Article  CAS  PubMed  Google Scholar 

  18. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ (1999) Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 43: 509–514

    Article  CAS  PubMed  Google Scholar 

  19. Kress JP, Pohlman AS, O’Connor MF, Hall JB (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342: 1471–1477

    Article  CAS  PubMed  Google Scholar 

  20. Leather HL (2004) Drug interactions in the hematopoetic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 33: 137–152

    Article  CAS  PubMed  Google Scholar 

  21. Karasu Z, Gurakar A, Carlson J, et al (2001) Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. J Okla State Med Assoc 94: 121–123

    CAS  PubMed  Google Scholar 

  22. McLaughlin GE, Gonzalez-Rossique M, Gelman B, Kato T (2000) Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant Proc 32: 665–668

    Article  CAS  PubMed  Google Scholar 

  23. Palkama VJ, Neuvonen PJ, Olkolla KT (1998) The CYP3A4 inhibitor itraconazole has no effect on the pharmacokinetics and pharmacodynamics of i.v. fentanyl. Br J Anaesth 81: 598–600

    CAS  PubMed  Google Scholar 

  24. Tempelhoff R, Modica P, Spitznagel E (1988) Increased fentanyl requirement in patients receiving long-term anticonvulsant therapy. Anesthesiology 69: A594 (abst)

    Article  Google Scholar 

  25. Beers R, Camporesi E (2004) Remifentanil update: clinical science and utility. CNS Drugs 18: 1085–1104

    Article  CAS  PubMed  Google Scholar 

  26. Anderson GD (2008) Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 30: 173–180

    Article  CAS  PubMed  Google Scholar 

  27. Holbrook AM, Pereira JA, Labiris R, et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165: 1095–1106

    Article  CAS  PubMed  Google Scholar 

  28. Schwarz UI, Ritchie MD, Bradford Y, et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358: 999–1008

    Article  CAS  PubMed  Google Scholar 

  29. Limdi NA, Veenstra DL (2008) Warfarin pharmacogenetics. Pharmacother 28: 1084–1087

    Article  CAS  Google Scholar 

  30. Ozawa S, Soyama A, Saeki M, et al (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19: 83–95

    Article  CAS  PubMed  Google Scholar 

  31. Stamer UM, Stüber F, Muders T, Musshoff F (2008) Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 107: 926–929

    Article  PubMed  Google Scholar 

  32. Gashe Y, Daaili Y, Fathi M, et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351: 2827–2837

    Article  Google Scholar 

  33. U.S. Food and Drug Administration. Center for Devices and Radiological Health consumer information. New device clearance. Roche Amplichip cytochrome P450 genotyping test and Affymetrix GeneChip Microarray Instrumentation System — K042259. Available from: http://www.fda.gov/cdrh/mda/docs/k042259.html Accessed, Nov 2008

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Department, University Hospital, Herestraat 49, 3000, Leuven, Belgium

    I. Spriet

  2. Medical Intensive Care Unit, University Hospital, Herestraat 49, 3000, Leuven, Belgium

    W. Meersseman

Authors
  1. I. Spriet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Meersseman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care Erasme Hospital, Universitée libre de Bruxelles, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Spriet, I., Meersseman, W. (2009). Relevant CYP450-mediated Drug Interactions in the ICU. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92278-2_79

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92278-2_79

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92277-5

  • Online ISBN: 978-0-387-92278-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation